Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common Candida Species by 용동은
Evaluation of Two Commercial Broth Microdilution Methods
Using Different Interpretive Criteria for the Detection of
Molecular Mechanisms of Acquired Azole and Echinocandin
Resistance in Four Common Candida Species
Ha Jin Lim,a Jong Hee Shin,a Mi-Na Kim,b Dongeun Yong,c Seung A. Byun,a Min Ji Choi,a Seung Yeob Lee,a
Eun Jeong Won,a,d Seung-Jung Kee,a Soo Hyun Kim,a,e Myung-Geun Shina
aDepartment of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hospital, Gwangju, Republic of Korea
bDepartment of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea
cDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Republic of Korea
dDepartment of Parasitology and Tropical Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea
eDepartment of Microbiology, Chonnam National University Medical School, Gwangju, Republic of Korea
ABSTRACT The abilities of the new Vitek 2 AST-YS08 (YS08) and Sensititre Yeast-
One (SYO) systems to detect the resistances of Candida isolates to azoles and echi-
nocandins were evaluated. In total, 292 isolates, including 28 Candida albicans (6
Erg11 and 2 Fks mutants), 57 Candida parapsilosis (26 Erg11 mutants), 24 Candida
tropicalis (10 Erg11 and 1 Fks mutants), and 183 Candida glabrata (39 Pdr1 and 13
Fks mutants) isolates, were tested. The categorical agreements (CAs) between the
Clinical and Laboratory Standards Institute (CLSI) method and YS08 fluconazole MICs
obtained using clinical breakpoints were 92.4% (C. albicans), 96.5% (C. parapsilosis),
and 87.0% (C. tropicalis), and the CAs between the CLSI and SYO MICs were 92.3%
(C. albicans), 77.2% (C. parapsilosis), 100% (C. tropicalis), and 98.9% (C. glabrata). For
C. glabrata, the CAs with the CLSI micafungin MICs were 92.4% and 55.5% for the
YS08 micafungin and caspofungin MICs, respectively; they were 100%, 95.6%, and
98.9% for the SYO micafungin, caspofungin, and anidulafungin MICs, respectively.
YS08 does not provide fluconazole data for C. glabrata; the CA with the CLSI flu-
conazole MIC was 97.8% for the YS08 voriconazole MIC, using an epidemiological
cutoff value (ECV) of 0.5 g/ml. Increased CAs with the CLSI MIC were observed for
the YS08 MIC using CLSI ECVs (for fluconazole and C. tropicalis, 100%; for micafungin
and C. glabrata, 98.9%) and for the SYO MIC using method-specific ECVs (for flu-
conazole and C. parapsilosis, 91.2%; for caspofungin and C. glabrata, 98.9%). There-
fore, the YS08 and SYO systems may have different abilities to detect mechanisms of
azole and echinocandin resistance in four Candida species; the use of method-
specific ECVs may improve the performance of both systems.
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Antifungal susceptibility testing (AFST) against Candida is useful for optimizing thetreatment of Candida bloodstream infections (BSIs) (1, 2). In the clinical microbi-
ology laboratory, two commercial broth microdilution (BMD)-based AFSTs, the Vitek 2
system (bioMérieux, Marcy l’Etoile, France) and the Sensititre YeastOne (SYO) system
(Thermo Scientific, Cleveland, OH, USA), are widely used, particularly for Candida BSI
isolates (3–6). The Vitek 2 system is a fully automated susceptibility testing system used
for both bacteria and yeasts in many laboratories and has the advantages of rapidity,
reduced costs, and ease of use (5–7). A new Vitek 2 AST-YS08 yeast susceptibility system
(referred to as YS08) was recently updated to reflect the revised species-specific clinical
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breakpoints (CBPs) defined by the Clinical and Laboratory Standards Institute (CLSI) for
common Candida species, but YS08 does not provide fluconazole MIC data for any of
the Candida glabrata isolates (7, 8). On the other hand, SYO, the colorimetric broth
microdilution method, has good concordance with the CLSI reference method for
Candida susceptibility testing (4, 9) but requires manual setup and visual reading of the
results (10, 11). To date, only one study has evaluated the new YS08 using revised CLSI
CBPs (8). In this study, the essential agreement (EA) and categorical agreement (CA)
between YS08 and SYO were suboptimal using 68 clinical Candida isolates skewed for
resistant isolates. They suggest that validation data with resistant isolates need to be
obtained (8).
Candida develops resistance to echinocandins through point mutations in the FKS1
(all Candida species) or FKS2 (C. glabrata only) gene, which are linked to resistance to
all three echinocandins, including micafungin, caspofungin, and anidulafungin (12, 13).
Several studies have evaluated the performance of echinocandin susceptibility testing
by using a panel of Candida isolates with and without known FKS mutation-related
echinocandin resistance mechanisms (14, 15), but there are limited data regarding the
evaluation of AFSTs for the detection of azole-resistant Candida isolates using molec-
ularly defined isolates (16). Multiple mechanisms of azole resistance, such as ERG11
mutations and overexpression of efflux pumps, have been reported for Candida albi-
cans, Candida parapsilosis, and Candida tropicalis (17–19); however, the overwhelming
singular mechanism of resistance identified in clinical isolates of C. glabrata is mutation
of the transcription factor PDR1, which leads to increased expression of multidrug
transporters that act as efflux pumps (20, 21).
The evaluation of AFST methods for Candida species is difficult, partly because the
results can be influenced by the composition of resistant Candida isolates within a
collection. When evaluation studies are performed using an abundance of antifungal-
susceptible isolates in the collection, very major errors (VMEs) and substantial major
discrepancies are uncommon, while errors are more common when studies are per-
formed using an abundance of resistant isolates (22, 23). In addition, CA between two
systems may vary depending on the interpretive criteria of the MICs used. Although
most commercial AFST systems use CLSI CBPs for categorical interpretation of MICs (24,
25; bioMérieux), method-specific epidemiological cutoff values (ECVs) have recently
been proposed as the interpretive criteria for SYO or Etest (26, 27). Given that the
performance of AFST relies on categorical interpretive criteria of the MIC results, we
performed a comparative evaluation of two commercial AFSTs (YS08 and SYO) and the
reference CLSI BMD method for the detection of azole- and echinocandin-resistant
isolates of four common Candida species, applying different MIC interpretive criteria,
including CLSI CBPs, CLSI ECVs, or the method-specific ECVs of SYO (SYO ECVs). We
tested a panel of well-characterized Candida strains from a South Korean collection
composed of 97 azole- or echinocandin-resistant isolates with molecularly defined
resistance mechanisms that reflect the antifungal resistance mechanisms most com-
monly identified in isolates of four common Candida species from South Korean
hospitals (19, 28); we also tested 195 control isolates without defined resistance
mechanisms. Furthermore, we evaluated the ability of voriconazole MIC determination
using YS08 to correctly detect fluconazole-resistant (FR) C. glabrata isolates.
RESULTS
Fluconazole testing for C. albicans, C. parapsilosis, and C. tropicalis. When 42 FR
isolates (6 FR C. albicans isolates harboring the K143R mutation in Erg11p, 26 C.
parapsilosis isolates harboring the Y132F mutation in Erg11p, and 10 FR C. tropicalis
isolates with ERG11 overexpression or the Y132F mutation in Erg11p) and 64
fluconazole-susceptible (FS) isolates (20 C. albicans, 31 C. parapsilosis, and 13 C. tropi-
calis isolates without defined resistance mechanisms) were tested, the EAs between the
CLSI M27 method and YS08 with fluconazole were 96.2%, 96.5%, and 100% for C.
albicans, C. parapsilosis, and C. tropicalis, respectively; the EAs between CLSI M27 and
SYO were 92.3%, 100%, and 95.7%, respectively (Table 1). When the categorical results
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for fluconazole with YS08 determined using two different interpretive criteria (CLSI
CBPs or ECVs) were compared to those produced by the CLSI method, the agreements
of YS08 using CLSI CBPs for C. albicans, C. parapsilosis, and C. tropicalis were 92.4%,
96.5%, and 87.0%, respectively; agreements determined using CLSI ECVs were 73.1%,
96.5%, and 100%, respectively. When the results for fluconazole produced by SYO were
compared to those produced by the CLSI method, the CAs of the fluconazole MICs
produced by SYO using CLSI CBPs for C. albicans, C. parapsilosis, and C. tropicalis were
92.3%, 77.2%, and 100%, respectively; the CAs obtained using SYO ECVs were 88.5%,
91.2%, and 100%, respectively.
Azole testing for C. glabrata. When the fluconazole MIC results for 91 isolates of
C. glabrata (39 FR isolates harboring a Pdr1 mutation and 52 fluconazole-susceptible,
dose dependent [F-SDD], isolates without Pdr1 mutations) obtained with SYO were
compared to those produced by the CLSI method, the CAs for fluconazole produced by
SYO using the CLSI CBPs and the SYO ECVs were 98.9% and 97.8%, respectively (Table
1). The EA for fluconazole between CLSI M27 and SYO was 95.6%. Because YS08 does
not provide fluconazole data for C. glabrata, the results for voriconazole obtained with
YS08 were used to predict the fluconazole susceptibility category for C. glabrata.
TABLE 1 CAs between fluconazole MICs obtained by the CLSI BMD method and those obtained by each of the two commercial BMD













No. (%) of isolates with
discrepanciesd
EA (%)eR or non-WT SDD S or WT VME ME Minor
C. albicans (26) Fluconazole CLSI M27 CLSI CBP (8) 23.1 0.0 76.9
YS08 CLSI CBP (8) 15.4 3.8 80.8 92.4 1 (3.8) 0 (0.0) 1 (3.8) 96.2
YS08 CLSI ECV (1) 42.3 57.7 73.1 1 (3.8) 6 (23.1) 0 (0.0)
SYO CLSI CBP (8) 30.8 0.0 69.2 92.3 0 (0.0) 2 (7.7) 0 (0.0) 92.3
SYO SYO ECV (2) 34.6 65.4 88.5 0 (0.0) 3 (11.5) 0 (0.0)
C. parapsilosis (57) Fluconazole CLSI M27 CLSI CBP (8) 45.6 0.0 54.4
YS08 CLSI CBP (8) 42.1 3.5 54.4 96.5 0 (0.0) 0 (0.0) 2 (3.5) 96.5
YS08 CLSI ECV (2) 49.1 50.9 96.5 0 (0.0) 2 (3.5) 0 (0.0)
SYO CLSI CBP (8) 24.6 15.8 59.6 77.2 4 (7.0) 0 (0.0) 9 (15.8) 100.0
SYO SYO ECV (4) 40.4 59.6 91.2 4 (7.0) 1 (1.8) 0 (0.0)
C. tropicalis (23) Fluconazole CLSI M27 CLSI CBP (8) 43.5 0.0 56.5
YS08 CLSI CBP (8) 30.5 13.0 56.5 87.0 0 (0.0) 0 (0.0) 3 (13.0) 100.0
YS08 CLSI ECV (2) 43.5 56.5 100.0 0 (0.0) 0 (0.0) 0 (0.0)
SYO CLSI CBP (8) 43.5 0.0 56.5 100.0 0 (0.0) 0 (0.0) 0 (0.0) 95.7
SYO SYO ECV (8) 43.5 56.5 100.0 0 (0.0) 0 (0.0) 0 (0.0)
C. glabrata (91) Fluconazole CLSI M27 CLSI CBP (64) 42.9 57.1
SYO CLSI CBP (64) 44.0 56.0 98.9 0 (0.0) 0 (0.0) 1 (1.1) 95.6
SYO SYO ECV (128) 40.7 59.3 97.8 2 (2.2) 0 (0.0) 0 (0.0)
Voriconazole YS08 P-CLSI ECV (1) 42.9 57.1 97.8 1 (1.1) 1 (1.1) 0 (0.0) NA
YS08 CLSI ECV (0.5) 58.2 41.8 82.4 1 (1.1) 15 (16.5) 0 (0.0)
aCLSI, Clinical and Laboratory Standards Institute; CLSI M27, CLSI M27-ED4 broth microdilution method (BMD); YS08, Vitek 2 AST-YS08 yeast susceptibility system; SYO,
Sensititre YeastOne system; CLSI CBP, clinical breakpoint provided by CLSI; ECV, epidemiological cutoff value; SYO ECV, method-specific ECV of SYO; P-CLSI ECV,
previous CLSI epidemiological cutoff value; R, resistant; non-WT, non-wild type; SDD, susceptible, dose dependent; S, susceptible; WT, wild type; CA, categorical
agreement; VME, very major error; ME, major error; minor, minor error; EA, essential agreement; NA, not available.
bThe values in parentheses denote interpretive fluconazole MIC criteria (in micrograms per milliliter) from the CLSI CBPs (MICs greater than or equal to the MIC for
resistance), CLSI ECVs (MICs greater than or equal to the non-WT MIC), or SYO ECVs (MICs greater than or equal to the non-WT MIC) against each Candida species
(27, 30, 34). The results for voriconazole obtained with YS08 were alternatively evaluated for C. glabrata isolates because YS08 does not provide fluconazole results
for C. glabrata. Although a CLSI clinical breakpoint is not yet proposed for voriconazole and C. glabrata, both the previous CLSI ECV (0.5 g/ml) and the revised CLSI
ECV (0.25 g/ml) were used (34, 45).
cEach of the categorical results were determined to indicate resistant, susceptible, dose dependent, and susceptible using speciesspecific CLSI CBPs of the CLSI M60,
1st edition, method (30) and as non-WT and WT using CLSI ECVs of the CLSI M59, 2nd edition, method (34) or the SYO ECVs (27).
dDetails regarding isolates with categorical errors obtained using CLSI CBPs were as follows. For C. albicans, YS08 misclassified two fluconazole-resistant (FR) isolates
harboring a K143R mutation in Erg11 as fluconazole susceptible, dose dependent (F-SDD), and fluconazole susceptible (FS; MIC, 0.5 g/ml), respectively. SYO
misclassified two FS isolates (MICs, 1 and 2 g/ml) as FR (MIC, 256 g/ml). For C. parapsilosis, YS08 misclassified two FR isolates harboring Y132F in Erg11 as F-SDD,
and SYO misclassified four and eight FR isolates as FS (MIC, 2 g/ml) and F-SDD, respectively, and one FS isolate (MIC, 2 g/ml) as F-SDD. For C. tropicalis, YS08
misclassified 3 FR isolates as F-SDD. For C. glabrata, SYO misclassified one F-SDD isolate (MIC, 8 g/ml) as FR (MIC, 64 g/ml).
eEssential agreement (2 log2 dilutions) between the MICs obtained by the CLSI M27 method and each of the Vitek 2 YS08 and YeastOne MICs.
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Although a species-specific CLSI CBP has not yet been proposed for voriconazole and
C. glabrata, categorical results for the YS08 voriconazole MICs based on the previous
CLSI ECV of 0.5 g/ml showed 97.8% agreement with the results of the CLSI method for
fluconazole, whereas the categorical result of YS08 for voriconazole based on the new
CLSI ECV (0.25 g/ml) showed 82.4% agreement with the results of the CLSI method for
fluconazole. Figure 1 shows that the voriconazole results obtained with YS08 with the
previous CLSI ECV (P-ECV; 0.5 g/ml) demonstrated a clearer separation between Pdr1
mutants and non-Pdr1 mutants than the results obtained with the new CLSI ECV
(N-ECV; 0.25 g/ml).
Echinocandin testing with YS08 and SYO. Table 2 summarizes the agreements
between the micafungin susceptibility results obtained by the CLSI method and those
obtained by each of the echinocandin tests with the YS08 or SYO method for 95 isolates
of three common Candida species. Two micafungin-resistant (MR) C. albicans isolates
and one MR C. tropicalis isolate harboring an Fks1 mutation were correctly classified as
resistant or non-wild type (non-WT) to both micafungin and caspofungin with YS08 or
SYO, irrespective of the interpretive criteria. Notably, one C. albicans isolate harboring
S645P in Fks1 showed an anidulafungin MIC value of 0.25 g/ml, which was misclas-
sified as susceptible in the anidulafungin test of SYO using the CLSI CBP; however, it
was correctly classified as non-WT to anidulafungin using the SYO ECVs. For 92 isolates
of C. glabrata (13 MR isolates harboring Fks mutations and 79 micafungin-susceptible
[MS] isolates without Fks mutations), the EA for micafungin between the CLSI M27
method and YS08 was 92.4%, while the EA between CLSI M27 and SYO was 97.8%.
Figure 2 depicts two scattergrams comparing the micafungin MICs for C. glabrata
isolates obtained by the CLSI method with the micafungin or caspofungin MICs
obtained with YS08, using the CLSI CBPs or ECVs. Because YS08 does not show
micafungin MIC results of 0.03 g/ml, a modified ECV of 0.06 g/ml instead of the
CLSI ECV (0.03 g/ml) was used for the micafungin and C. glabrata combination (Fig.
2A). For assessment of the caspofungin MICs obtained with YS08, only the CLSI CBP was
used because of the lack of a CLSI ECV for caspofungin (Fig. 2B). The categorical results
for the YS08 micafungin MIC obtained using the CLSI CBP showed that 7 out of 13 MR
C. glabrata isolates with Fks mutation were misclassified as micafungin intermediate (six
isolates) or MS (one isolate), whereas all 79 MS isolates were correctly classified as
susceptible, resulting in a CA of 92.4% with the CLSI micafungin MIC. The categorical
results for the YS08 micafungin MIC obtained using a modified ECV of 0.06 g/ml
showed that 12 of 13 MR isolates were correctly classified as non-WT, resulting in a CA
of 98.9% with the CLSI micafungin MIC results. The categorical results for the YS08
FIG 1 A scattergram comparing the fluconazole MICs obtained by the Clinical and Laboratory Standards
Institute (CLSI) method and voriconazole MICs obtained with the Vitek 2 AST-YS08 (YS08) system.
Numbers represent the number of isolates of Candida glabrata at each MIC pair. The gray zone indicates
fluconazole-resistant Pdr1 mutants of C. glabrata. The voriconazole MIC results obtained with YS08 with
the previous CLSI ECV (P-ECV; 0.5 g/ml) showed a clearer separation between Pdr1 mutants and
non-Pdr1 mutants than those obtained with the new CLSI ECV (N-ECV; 0.25 g/ml).
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caspofungin MIC obtained using the CLSI CBP did not differentiate between MR and MS
isolates of C. glabrata, resulting in a CA of 55.5% with the CLSI micafungin MIC results.
Figure 3 demonstrates that all three echinocandin (micafungin, caspofungin, and
anidulafungin) tests with SYO showed excellent performance (95%) to differentiate
between MR Fks mutants of C. glabrata and MS non-Fks mutants, irrespective of the
MIC interpretive criteria. The CA of SYO for micafungin was 100% using both the CLSI
CBP and SYO ECV, while the CA of SYO for caspofungin was 95.6% using the CLSI CBP
and 98.9% using the SYO ECV. In addition, the CAs of anidulafungin for C. glabrata
obtained with SYO using the CLSI CBP and the SYO ECV were both 98.9%.
DISCUSSION
By testing 292 isolates of four common Candida species with or without molecular
mechanisms of acquired azole and echinocandin resistance, the present study revealed
TABLE 2 CAs of micafungin results obtained by the reference CLSI BMD method and echinocandin (micafungin, caspofungin, or















No. (%) of isolates with
discrepancies
EA (%)eR or non-WT I S or WT VME ME Minor
C. albicans (2) Micafungin CLSI M27 CLSI CBP (1) 100.0
YS08 CLSI CBP (1) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0) 100.0
YS08 M-CLSI ECV (0.12) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
SYO CLSI CBP (1) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0) 100.0
SYO SYO ECV (0.12) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
Caspofungin YS08 CLSI CBP (1) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
SYO CLSI CBP (1) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
SYO SYO ECV (0.5) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
Anidulafungin SYO CLSI CBP (1) 50.0 50.0 50.0 1 (50.0)d 0 (0.0) 0 (0.0)
SYO SYO ECV (0.25) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
C. tropicalis (1) Micafungin CLSI M27 CLSI CBP (1) 100.0
YS08 CLSI CBP (1) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0) 100.0
YS08 CLSI ECV (0.12) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
SYO CLSI CBP (1) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0) 100.0
SYO SYO ECV (0.12) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
Caspofungin YS08 CLSI CBP (1) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
SYO CLSI CBP (1) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
SYO SYO ECV (0.5) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
Anidulafungin SYO CLSI CBP (1) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
SYO SYO ECV (1) 100.0 100.0 0 (0.0) 0 (0.0) 0 (0.0)
C. glabrata (92) Micafungin CLSI M27 CLSI CBP (0.25) 14.1 85.9
YS08 CLSI CBP (0.25) 6.5 6.5 87.0 92.4 1 (1.1) 0 (0.0) 6 (6.5) 92.4
YS08 M-CLSI ECV (0.12) 13.0 87.0 98.9 1 (1.1) 0 (0.0) 0 (0.0)
SYO CLSI CBP (0.25) 14.1 85.9 100.0 0 (0.0) 0 (0.0) 0 (0.0) 97.8
SYO SYO ECV (0.06) 14.1 85.9 100.0 0 (0.0) 0 (0.0) 0 (0.0)
Caspofungin YS08 CLSI CBP (0.5) 13.0 40.2 46.8 55.5 0 (0.0) 4 (4.3) 37 (40.2)
SYO CLSI CBP (0.5) 15.2 3.3 81.5 95.6 0 (0.0) 1 (1.1) 3 (3.3)
SYO SYO ECV (0.5) 15.2 84.8 98.9 0 (0.0) 1 (1.1) 0 (0.0)
Anidulafungin SYO CLSI CBP (0.5) 13.0 87.0 98.9 1 (1.1) 0 (0.0) 0 (0.0)
SYO SYO ECV (0.25) 13.0 87.0 98.9 1 (1.1) 0 (0.0) 0 (0.0)
aCLSI, Clinical and Laboratory Standards Institute; CLSI M27, CLSI M27-ED4 broth microdilution method; YS08, Vitek 2 AST-YS08 yeast susceptibility system; SYO,
Sensititre YeastOne system; CLSI CBP, clinical breakpoint provided by the CLSI; ECV, epidemiological cutoff value; M-CLSI ECV, modified CLSI ECV; SYO ECV, SYO-
specific ECV; R, resistant; non-WT, non-wild type; I, intermediate; S, susceptible; WT, wild type; CA, categorical agreement; VME, very major error; ME, major error;
minor, minor error; EA, essential agreement.
bThe values in parentheses denote interpretive echinocandin MIC criteria (in micrograms per milliliter) from the CLSI CBPs (MICs greater than or equal to the MIC for
resistance), CLSI ECVs (MICs greater than or equal to the non-WT MIC), or SYO ECVs (MICs greater than or equal to the non-WT MIC) against each Candida species
(26, 30, 34). Because YS08 does not give the micafungin MIC results of 0.03 g/ml, a modified ECV of 0.06 g/ml instead of the CLSI ECV (0.03 g/ml) was used for
micafungin for YS08.
cEach of the categorical results were determined to indicate resistant, intermediate, and susceptible using the species-specific CLSI CBPs of the CLSI M60, 1st edition,
method (30) and as non-WT and WT using the CLSI ECVs of the CLSI M59, 2nd edition, method (34) or SYO ECVs (26).
dOne C. albicans harboring Fks1 S645P was misclassified as susceptible in the SYO anidulafungin test using the CLSI CBP.
eEssential agreement (2 log2 dilutions) between the MICs obtained by the CLSI M27 method and each of the Vitek 2 YS08 and YeastOne MICs.
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the different abilities of the YS08 and SYO systems to detect various mechanisms of
azole and echinocandin resistance. YS08 showed performance characteristics superior
to those of SYO for the detection of FR C. parapsilosis isolates harboring the Y132F
mutation in Erg11p, but caspofungin testing with YS08 seemed to be unreliable for C.
glabrata. SYO showed excellent performance for all three echinocandins, irrespective of
the interpretive criteria used, CLSI CBPs or SYO ECVs. This is the first study to show that
YS08 voriconazole testing may be used as a surrogate marker for fluconazole testing of
C. glabrata and that the use of method-specific ECVs may improve the performance of
commercial AFST systems.
We found excellent (90%) EAs and CAs for the fluconazole MICs between the CLSI
method and the YS08 or SYO method for three species, including C. albicans, C.
parapsilosis, and C. tropicalis; however, the CA of YS08 was 87.0% for C. tropicalis and
the CA of SYO was 77.2% for C. parapsilosis. The only minor errors (13%) of YS08 with
fluconazole were observed with C. tropicalis due to the misclassification of 3 of 10 FR
isolates as F-SDD, suggesting that the F-SDD results from the fluconazole test of YS08
should be interpreted cautiously for C. tropicalis. A Y132F amino acid substitution in
Erg11p is reportedly the most frequent fluconazole resistance mechanism in clinical
FIG 2 Two scattergrams comparing the micafungin MICs obtained by the CLSI method and the micafungin (A) or
caspofungin (B) MICs obtained with the Vitek 2 AST-YS08 (YS08) system. Numbers represent the number of isolates
of Candida glabrata at each MIC pair. The gray zone indicates micafungin-resistant Fks mutants of C. glabrata. The
resistant (R), intermediate (I), and susceptible (S) designations represent categorical MIC interpretations determined
by the use of CLSI clinical breakpoints (CLSI CBPs). The micafungin MIC results obtained with YS08 with the
modified CLSI ECV (M-ECV; 0.06 g/ml) showed a clearer separation between Fks mutants and nonmutants than
those obtained with YS08 with the CLSI CBP (A), whereas the caspofungin MIC results obtained with YS08 did not
discriminate between Fks mutants and nonmutants (B).
FIG 3 Three scattergrams of the micafungin MICs obtained by the CLSI method versus the micafungin (A), caspofungin (B), and anidulafungin (C) MICs obtained
by the Sensititre YeastOne (SYO) system. Numbers represent the number of isolates of Candida glabrata at each MIC pair. The gray zone indicates
micafungin-resistant Fks mutant isolates of C. glabrata. The resistant (R), intermediate (I), and susceptible (S) designations represent the categorical MIC
interpretations determined by the use of CLSI clinical breakpoints (CLSI CBPs). The SYO results obtained for all three echinocandins, including micafungin,
caspofungin, and anidulafungin, correctly discriminated Fks mutants and nonmutants of C. glabrata (95%), irrespective of the interpretive criteria used, i.e.,
CLSI CBPs or SYO-specific ECVs (S-ECV).
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isolates of C. parapsilosis in South Korea; this substitution has also been reported in
Brazil, the United States, and Kuwait (28). In a recent Italian study, SYO was able to
correctly detect FR C. parapsilosis isolates harboring the Y132F ERG11 gene (Y132F
isolates), in which the fluconazole MICs for most (44 of 49 isolates) Y132F isolates were
64 g/ml using the SYO method; all but 1 of the isolates were also resistant to
voriconazole using the CLSI method (29). Notably, the fluconazole MICs of most Y132F
isolates in the present study were 8 to 16 g/ml using the CLSI (24 of 26 isolates) or
YS08 (24 of 26 isolates) method, and only 7.7% of them were resistant to voriconazole
and 80.8% were susceptible, dose dependent (SDD), to voriconazole by the CLSI
method (data not shown); therefore, SYO does not efficiently detect Y132F isolates with
lower fluconazole MICs. These results indicate that YS08 appears to be a superior
method for the detection of FR C. parapsilosis isolates harboring a Y132F mutation in
Erg11p from the South Korean collection.
According to the revised CLSI CBP, C. glabrata isolates are no longer considered
susceptible to fluconazole but are classified only as either F-SDD or FR (30). In the
present study, the fluconazole test with SYO was able to differentiate between 39 FR
isolates and 52 F-SDD isolates of C. glabrata, resulting in a CA of 98.9% with the CLSI
method. However, the new YS08 does not provide fluconazole results for C. glabrata.
A previous study showed that the CA for fluconazole between the Vitek 2 AF03 yeast
susceptibility test and the CLSI BMD method was greater than 90% for all Candida
species except C. glabrata (87.8%) (23). A recent study also showed that a modified
YS08 to assess the adequacy of fluconazole MICs for C. glabrata by setting the tested
isolates to C. albicans within the Vitek 2 software produced VMEs (3 of 26 isolates)
compared to the results obtained with the previous version of the Vitek 2 AST-YS07
card (7). This suggests the need for an alternative approach to detect FR C. glabrata
isolates with YS08.
Acquired resistance to both fluconazole and voriconazole in C. glabrata is mostly
governed by a single mechanism through a gain-of-function mutation in the transcrip-
tion factor for Pdr1p, regulating the drug-efflux transporter genes (20). Accordingly,
cross-resistance between fluconazole and voriconazole in C. glabrata has already been
reported (31, 32); in one study, 98.8% of FR isolates were not susceptible to voricona-
zole (MIC  0.5 g/ml) (32). Given that the Infectious Diseases Society of America
guidelines for the management of candidiasis recommend routinely performing AFST
for determination of C. glabrata susceptibility to azoles and echinocandins (1), we
alternatively investigated the voriconazole MIC determination of YS08 to correctly
discriminate FR C. glabrata isolates harboring a Pdr1 mutation from F-SDD isolates
without Pdr1 mutations. Because a CLSI CBP for the voriconazole-C. glabrata combi-
nation has not been proposed, we used both the previous and the new CLSI ECVs (0.5
and 0.25 g/ml, respectively) to differentiate wild-type (WT) from non-WT strains of C.
glabrata. The voriconazole result obtained with YS08 with the previous CLSI ECV
(0.5 g/ml) showed a clearer separation between Pdr1 mutants and non-Pdr1 mutants,
resulting in a CA of 97.8% with the results for fluconazole by the CLSI method, while the
CA of the YS08 voriconazole test using the new ECV (0.25 g/ml) was only 82.4%. These
findings indicate that the use of the YS08 voriconazole test with an ECV of 0.5 g/ml
could provide a reliable discrimination between Pdr1 mutants and non-Pdr1 mutants of
C. glabrata for clinical laboratories.
Because the significant interlaboratory variability of the in vitro caspofungin test by
the reference CLSI BMD method contributes to false resistance, the echinocandin
results obtainded with the two systems were compared to the micafungin results
obtained using CLSI methods (30, 33). When the micafungin and caspofungin MIC
results obtained with YS08 were compared to the micafungin MIC results for C. glabrata
produced by the CLSI method, the CA of YS08 for micafungin was 92.4% using the CLSI
CBP, whereas it was 55.5% for the YS08 caspofungin test. Our findings are consistent
with the results of a recent study in which the YS08 caspofungin test for C. glabrata had
low CAs (5/15 isolates) with the SYO caspofungin test, although the results for the
isolates that they evaluated were not molecularly confirmed (8). In the YS08 instruc-
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tions, the Vitek 2 system also recommends the use of an alternative method before
reporting YS08 caspofungin test results for C. glabrata (bioMérieux). All of these
findings confirm that YS08 micafungin test results are more reliable than YS08 caspo-
fungin test results.
The CBPs classify isolates as susceptible or resistant, while the ECVs are useful for
distinguishing between WT isolates without resistance mechanisms and non-WT iso-
lates harboring resistance mechanisms (34). Both CBPs and ECVs can be used to
determine the CA between any two methods. When the micafungin, caspofungin, and
anidulafungin MIC results for all 95 isolates (16 Fks mutants and 79 nonmutants) of
three Candida species produced by SYO were compared to the micafungin MIC results
produced by the CLSI method, excellent CAs (95%) were found for all three echino-
candins, irrespective of the interpretive criteria used, i.e., CBPs or SYO ECVs. Notably, the
CA of the SYO caspofungin test results for C. glabrata were 95.6% using the CLSI CBP
and 98.9% using the SYO ECV. In addition, the CAs of the SYO fluconazole test results
for C. glabrata were 77.2% using the CLSI CBP and 91.2% using the SYO ECV, suggesting
that the use of method-specific ECVs may improve the performance of SYO.
YS08 uses CLSI CBPs for interpreting the results for azoles or echinocandins. Using
CLSI CBPs, the fluconazole test for C. tropicalis with YS08 showed a 13.0% minor error
rate without VMEs or major errors (ME); the micafungin test for C. glabrata with YS08
showed a 6.5% minor error rate with 1.1% VMEs. The reasons for the high rates of minor
errors for YS08 are not fully clear, but the discrepancies may reflect the tendency of the
YS08 MIC results to be slightly lower than the CLSI or SYO MIC results. We found that
adjusting the fluconazole CLSI ECV of 1 g/ml for C. tropicalis improved the perfor-
mance of YS08, yielding a CA of 100% and reducing the minor error rate from 13.0% to
0%. In addition, we applied a modified ECV of 0.06 g/ml to the YS08 micafungin test
for C. glabrata, which reduced the minor error rate from 6.5% to 0%, while it increased
the CA from 92.4% to 98.9%. Therefore, we emphasize that erroneous results may be
observed if the results obtained by one method are interpreted by use of the ECVs/CBPs
determined for another method. Considering that echinocandin resistance is more
frequently found among C. glabrata isolates worldwide (35) than among other Candida
species, we suggest that broadening the micafungin MIC detection range to 0.03 g/ml
and applying the CLSI ECV (0.03 g/ml) for micafungin and C. glabrata might further
improve the performance of YS08 for the detection of echinocandin resistance. In
addition, YS08 will be most useful if either method- or species-dependent ECVs are
available for the Candida isolate and antifungal agent evaluated, such as SYO (26, 27).
MATERIALS AND METHODS
Fungal isolates. A total of 292 clinical isolates of four common Candida species from a South Korean
collection were tested. Table 3 described the 292 isolates evaluated in this study. The South Korean
collection of Candida isolates included 284 BSI isolates and 8 isolates from other clinical specimens (4
from urine, 1 from ascitic fluid, 1 from sputum, 1 from skin, and 1 from ear pus) submitted to Chonnam
National University Hospital, Gwangju, South Korea, from several South Korean hospitals during a
nationwide surveillance conducted in South Korea (2003 to 2018) (19, 28, 36, 37). Candida isolates were
identified to the species level using biochemical tests, matrix-assisted laser desorption ionization–time of
flight mass spectrometry, and/or molecular methods (37, 38). For all Candida isolates, antifungal MICs
were determined using the CLSI M27, 4th edition (M27-ED4), broth microdilution method (39). Sequence
analyses of ERG11 and three transcription factor genes (TAC1, MRR1, and UPC2) were performed for all 26
C. albicans and 57 C. parapsilosis isolates, irrespective of their fluconazole susceptibility (28, 40); the
expression levels of CDR1, MDR1, and ERG11 were quantified, and the ERG11 and UPC2 genes were
sequenced for all 23 isolates of C. tropicalis (19). The PDR1 genes were sequenced for all 39 FR isolates
and 52 F-SDD isolates of C. glabrata (41). The FKS1 (for Candida species) and FKS2 (for C. glabrata) genes
were sequenced for both the 16 MR isolates of three Candida species and the 79 MS C. glabrata isolates
(42, 43). All isolates were stored at 70°C in Trypticase soy broth supplemented with 15% glycerol until
they were tested. These isolates were passaged twice on potato dextrose agar at 35°C prior to testing.
Antifungal susceptibility testing. The antifungal MICs for each isolate were determined by three
methods: by the CLSI M27-ED4 BMD method and with the Vitek 2 and Sensititre systems. For all Candida
isolates, the MICs of fluconazole and micafungin were redetermined by the CLSI M27-ED4 broth
microdilution method after 24 h of incubation; they were defined as the lowest concentrations that
produced an approximately 50% growth reduction compared to the growth of a drug-free control (39).
The Vitek 2 system AST-YS08 and the Sensititre YeastOne YO10 system were used following the
manufacturers’ instructions (25; bioMérieux). The ranges of antifungal drug concentrations used to
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determine the MICs for fluconazole, voriconazole, micafungin, and caspofungin were 0.5 to 64 g/ml,
0.12 to 8 g/ml, 0.06 to 8 g/ml, and 0.12 to 8 g/ml, respectively, for YS08, and those for fluconazole,
micafungin, caspofungin, and anidulafungin were 0.12 to 256 g/ml, 0.008 to 8 g/ml, 0.008 to 8 g/ml,
and 0.015 to 8 g/ml, respectively, for SYO. Antifungal MICs were automatically determined with the
Vitek 2 system, while the MIC endpoints in the SYO were visually determined after 24 h of incubation as
changes in color (purple or blue) from that for the drug-free control growth (red). Two reference strains
(C. parapsilosis ATCC 22019 and Candida krusei ATCC 6258) were tested in each antifungal susceptibility
test as quality control isolates. The reproducibility of YS08 was determined by testing five isolates (C.
albicans ATCC 64550, C. parapsilosis ATCC 22019, C. tropicalis ATCC 750 and ATCC 201380, and C. glabrata
ATCC 90030) in triplicate on three different days (44); the results showed 100% reproducibility for all
azole and echinocandin agents.
Data analyses. EA was determined with respect to the MIC results of YS08 and SYO, with EA being
a result within 2 dilutions (two wells) of the result obtained by CLSI BMD. The MIC results obtained
byYS08 were interpreted according to two criteria, including CLSI CBPs and CLSI ECVs (Tables 1 and 2)
(30, 34, 45). The MIC results obtained with SYO were interpreted according to two criteria, including CLSI
CBPs and SYO ECVs (26, 27, 30). CA was defined as the percentage of isolates classified by the two
commercial tests into the same susceptible (or WT) or resistant (or non-WT) category into which they
were classified by the CLSI reference method. Errors were considered VMEs when an isolate classified as
“resistant” by the CLSI method using the CLSI CBP was categorized as “susceptible” or “WT” by a test, MEs
when an isolate classified as “susceptible” by the CLSI method using the CLSI CBP was classified as
“resistant” or “non-WT” by a test, and minor errors for other discordances.
Ethics statement. This study was approved by the Institutional Review Board of Chonnam National
University Hospital (approval number CNUH-2018-120).
Data availability. The new Pdr1 sequences of FR C. glabrata isolates have been deposited in
GenBank with accession numbers MT077187, MT077189, MT077190, MT077193, MT077196, MT077197,
MT077200, MT077202, MT077205 to MT077207, MT090722, MT090725, MT090726, MT090728 to
MT090735, MT090737, and MT090738 (24 isolates), while the Fks sequence has been given GenBank
accession number MT090721 (1 isolate) (Table 3).
TABLE 3 Resistance mechanisms and categorical results for fluconazole and micafungin by the CLSI M27 method for all 292 isolates of
four common Candida species evaluated in this studya
Candida
species
Result by CLSI M27b
Defined mechanism(s) of resistance
No. of isolates
Drug Category Blood Other Total
C. albicans Fluconazole R Erg11, K143R mutation 5 1 6
S No mutations (Erg11, Tac1, Mrr1, and Upc2) defined 16 4 20
Micafungin R Fks1, S645P mutation 2 2
C. parapsilosis Fluconazole R Erg11, Y132F mutation 26 26
S No mutations (Erg11, Tac1, Mrr1, and Upc2) defined 31 31
C. tropicalis Fluconazole R ERG11 overexpression 6 3 9
R Erg11, Y132F mutation 1 1
S No mutations (Erg11 and Upc2) defined 13 13
Micafungin R Fks1, S654S/P 1 1
C. glabrata Fluconazole R Pdr1 mutations N132S, G1099S (1),c S236N (1), P258L (1), P258S (2),
V260A (1), L280S (1), S316I (1), P327L (1), S337F (1), E340G,
D919Y (1), E340K (1), G346S (2), L347F (2), L366P, E555D (1),
A731I (1), R376Q (1), S391L (1), Y556C (1), H576Y (2), Y584D (1),
E714D (1), T752I (1), N768D (2), R772K (1), K776E (1), G788W (1),
L825P (1), F832L, L833V (1), Y932C (1), G943S (1), S947L (1),
D954E (1), T1080N (1), and G1088E (1)
39 39
SDD No Pdr1 mutation 52 52
Micafungin R Fks mutations Fks1, S629P (1),c Fks1, P633T and Fks2, D666N (1),
Fks2, S663P (8), Fks2, R665G (1), Fks2, I661_S662insFL (1), Fks2,
and P667T (1)
13 13
S No Fks1 or Fks2 mutations 79 79
Total Fluconazole R/SDD Presence of defined azole resistance mechanisms 77 4 81
SDD/S No azole mutation defined 112 4 116
Micafungin R Fks1 or Fks2 mutations 16 16
S No Fks1 or Fks2 mutations 79 79
aCLSI, Clinical and Laboratory Standards Institute; R, resistant; S, susceptible; SDD, susceptible, dose dependent.
bAntifungal MICs were obtained by the CLSI M27-ED4 broth microdilution method (39) and categorized using the CLSI M60, 1st edition, method (30).
cNumbers in parentheses indicate the number of strains with that resistance mechanism. The new Pdr1 sequences of FR C. glabrata isolates have been deposited in
GenBank with accession numbers MT077187, MT077189, MT077190, MT077193, MT077196, MT077197, MT077200, MT077202, MT077205 to MT077207, MT090722,
MT090725, MT090726, MT090728 to MT090735, MT090737, and MT090738 (24 isolates); the Fks sequence has been given GenBank accession number MT090721 (1
isolate).
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